Your cart
There are no more items in your cart
SKINOREN CREAM 30G 20%
025915012
1 Item
Last items in stock
€16.22
€16.22
€18.90
-€2.68
€16.22
Bench drugs Skinoren cream 30g 20%
SKINOREN 20% CREAM
active ingredients
1 g of Skinoren cream contains 200 mg (20%) of azelaic acid. Excipients with known effects: benzoic acid, propylene glycol. For the full list of excipients, see paragraph 6.1.Excellent
Benzoic acid (E210) Cetearil octanoate + Isopropyl miristate (PCL Liquid) Glycerol 85% Glyceryl stearate + cetearil alcohol + cetil palmitato + cocoglycerides (CUTINA CBS) Propylene glycol Purified water Stearoil macrogolglyceridesTherapeutic indications
Treatment of acne (acne vulgaris) in its various expressions characterized by the presence of comedons, papules, pustulas, small nodules.Contraindications
Hypersensitivity to the active ingredient or any of the excipients listed in paragraph 6.1.Population
Method of administration Skin use. Population Skinoren cream should be applied on areas to treat skin twice a day (morning and evening) making it penetrate with a light massage. Approximately 2.5 cm of cream are enough to treat the whole face. Before applying Skinoren cream thoroughly wash the skin with water and dry it. It is also possible to use a delicate skin cleanser. It is important to use Skinoren cream regularly throughout the duration of treatment. The duration of treatment with Skinoren cream may vary from patient to patient and depending on the severity of the pathology. To achieve optimal results, Skinoren cream must be used for several months continuously. There are clinical experiences related to the continuous application of Skinoren cream up to a year. In patients with acne, an obvious improvement is generally observed after about 4 weeks. In case of skin irritation (see section 4.8 “Unwanted Effects”), decrease the amount of cream for each application, or reduce the frequency of use of Skinoren cream at once a day until the disappearance of the irritative phenomenon. If necessary, suspend treatment for a few days. After a short period of treatment without appreciable results, a medical evaluation is required. Pediatric population Use in teenagers (12 - 18 years). There are no variations in posology when Skinoren cream is applied in teenagers with an age between 12 and 18 years. The safety and effectiveness of Skinoren cream in children under 12 years has not been proven. Geriatric population No targeted studies have been conducted on patients aged 65 or over. Patients with liver disease No targeted studies have been conducted on patients with liver disease. Patients with kidney disease No targeted studies have been conducted on patients with kidney disease.Conservation
Do not store at temperature above 25°C.Warnings
Only for external use. It is necessary to pay attention during the use of Skinoren cream to avoid contact with eyes, mouth and other mucous membranes, and to properly instruct patients in this regard (see paragraph 5.3 “Preclinical safety data”). In case of accidental contact, the eyes, mouth and/or mucous membranes concerned must be washed with plenty of water. If the eye irritation persists, consult a doctor. Wash your hands after every application of Skinoren cream. Skinoren cream contains 2 mg of benzoic acid per gram. Benzoic acid can cause local irritation. Skinoren cream contains 125 mg of propylene glycol per gram. Maximum limit the concomitant use of cosmetic preparations, alcoholic or aggressive detergents, dyes, astringent or abrasive substances or exfoliating agents during treatment. During post-marketing surveillance, asthma has rarely been worsened in patients treated with azelaic acid (see paragraph 4.8).Interactions
No interaction studies have been conducted.Effects
The most frequently observed side effects in clinical studies and post-marketing surveillance include burning, itching, and erythema at the application site. The frequency of undesirable effects observed during clinical studies and post-marketing surveillance listed in the next table are defined in accordance with the MedDRA Frequency Convention: Very common (≥1/10) Common (≥1/100,Overdosing
Given the very low toxicity of azelaic acid, locally and systematically, it is unlikely that an intoxication occurs.Pregnancy
There are no adequate and controlled studies relating to the topical application of azelaic acid in pregnant women. Animal studies indicate the possibility of effects related to pregnancy, embryo-fetal development, childbirth or post-birth development. However, dose levels without harmful effects observed in animals in the study were 3-32 times the recommended maximum dose for man calculated on the body surface area. (see paragraph 5.3 ”Preclinical Security Data”). Caution should be observed when prescribing azelaic acid in pregnancy.Food
It is not known if in live azelaic acid is excreted in breast milk. However a test in vitro performed with dialysis technique to balance has shown that the drug can pass into breast milk. The distribution of azelaic acid in breast milk, however, is not expected to cause a significant change compared to the basal levels of azelaic acid present in milk. Since azelaic acid is not concentrated in milk and less than 4% of azelaic acid applied topically is absorbed at systemic level, there is no increase in exposure to endogenous azelaic acid above physiological levels. However it should be paid attention when Skinoren cream is given during breastfeeding. Babies should not come into contact with the skin/breast treated with the product.Fertility
Data on the effects of Skinoren cream on human fertility are not available. The results obtained by animal studies have shown no effect on fertility in male or female rats (see paragraph 5.3 Safety preclinical data).Source: Farmadati
- Deductible product
- Yes
025915012
1 Item
New
No reviews